Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles For Members Only Biopharma Hedge Funds Cool After Breakout Year Stephen Taub CalPERS Promotes Anton Orlich to Private Markets Deputy CIO James Comtois Capital Markets, Reframed: A Corporate Defined Benefit Perspective Sponsored by Fidelity Investments